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Introduction
In the pathophysiology of juvenile idiopathic arthritis
(JIA), T cells play an important role. The balance between
immune activation, governed by effector T cells (Teff) and
immune regulation, governed by regulatory T cells (Treg),
is disturbed. Low-dose methotrexate (MTX) is the most
commonly used drug to induce disease remission in JIA.
Nevertheless, despite its use for decades as the prime anti-
inflammatory drug, its immunomodulatory actions in vivo
remain poorly elucidated. We hypothesized that MTX
restores the immune balance by increasing Treg number
and suppressive function and decreasing Teff activation
status and effector functions.
Aim
To determine the immunomodulatory effects of MTX
on Treg and Teff in JIA during MTX treatment.
Methods
Peripheral blood mononuclear cells (PBMCs) of JIA
patients were isolated before MTX start (T0), at 3 (T3)
and 6 months (T6) during MTX treatment. Frequency
and phenotype of CD4+FoxP3+ Treg were analyzed ex
vivo by flow cytometry, and their suppressive function
was analyzed in CFSE suppression assays. Proliferation of
CD4+ and CD8+ Teff was determined with CFSE, upon a
5-day culture in the presence of a-CD3. Cytokine produc-
tion was measured ex vivo upon short PMA/ionomycin
stimulation by flow cytometry as well as in 5-day culture
supernatants and in plasma by luminex.
Results
Treg frequency and suppressive capacity did not
increase during MTX treatment. Frequency of naïve
CD4+CD45RA+ Teff increased, whereas the memory
CD45RO+ Teff decreased at T3 vs. T0. CD4+ and CD8+
Teff proliferation was significantly increased at T6
(mean: 75.3 +/- SD 14.9) vs. T0 (mean: 58.5 +/- SD 17.9)
(p=0.002) in patients with good and poor MTX response.
Ex vivo and supernatant cytokines showed no differences
between time-points, however plasma IFNg was markedly
increased at T6 vs. T3 and T0.
Conclusion
We observed no effects of MTX on Treg. In contrast to
our hypothesis, Teff increased their proliferation during
6 months of MTX treatment, which was accompanied by
increased plasma IFNg. Taken together, this suggests
immunomodulatory rather than immunosuppressive
effects of low-dose MTX treatment in JIA. We are now
investigating the role of antigen-presenting cells in
increased T cell proliferation during MTX treatment.
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